PTC Therapeutics, Inc. PTCT
NASDAQ · United States · Health Technology
$63.78-1.00 (-1.54%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Leading CIOs and CISOs honored for leadership, innovation, and business impact at the Philadelphia ORBIE Awards on September 25, 2026 at Philadelphia Marriott Downtown. PHILADELPHIA, Sept. 28, 2026 (GLOBE NEWSWIRE) -- The 2026 Philadelphia ORBIE Awards honored leading chief information officers (CIOs) and chief information security officers (CISOs) from CSL Behring, PTC Therapeutics, The School District of Philadelphia, Riggs Distler, OceanFirst Bank, Trinseo, Children's Hospital of Philadelphia
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept. 22, 2026, the company approved non-statutory stock options to purchase an aggregate of 51,270 shares of its common stock and 37,995 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 37 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.